|
|
|
Phase III Clinical Trial
DIA-AID 1 (DiaPep277®-Arresting Immune Diabetes)
DIA-AID is a phase III clinical study in newly diagnosed type 1 diabetes patients which is currently being conducted at 40 sites in Europe, Israel, and South Africa. A total of 456 newly diagnosed adult and adolescent patients have successfully been recruited to the study for a treatment period of two years.
Current Status
Patient recruitment has been completed and the study is ongoing. DIA-AID 1 is scheduled to end in 2011.
ClinicalTrials.gov
DIA-AID 1 - Extension Studies
Israel
Patients who completed 24 months of therapy in the DIA-AID phase III clinical study and still maintain residual beta cell function are eligible to enter an extension study where they will be treated with DiaPep277® regardless of their original cohort. This is an open label study where patients will be treated with 1 mg of the drug every three months for two years. The study has been initiated at three medical centers in Israel.
Europe
The study is an open-label extension study offering patients who participated and completed the previous 901 Study to continue treatment with DiaPep277® and clinical follow-up, for an additional 2 years. Only patients who completed the previous 2-year study who still have beta-cell function above a threshold level will be eligible for this extension study.
Study Steering Committee
- Prof. Itamar Raz
Hadassah Medical Center
Jerusalem, Israel
- Prof. Paolo Pozzilli
Università Campus Bio-Medico di Roma
Rome, Italy
- Prof. Thomas Linn
Universitätsklinikum Giessen
Giessen, Germany
- Prof. Francois Bonnici
New Groote Schuur Hospital
Capetown, South Africa
|
|
|
